Ser225
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.7
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser225  -  ARHGEF6 (human)

Site Information
KSSERPLsPkAVkGF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 456738

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 4 ) , mass spectrometry ( 1 , 3 , 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 14 ) , mutation of modification site ( 4 ) , western blotting ( 4 )
Disease tissue studied:
breast cancer ( 5 ) , breast ductal carcinoma ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 5 ) , leukemia ( 11 , 12 ) , acute myelogenous leukemia ( 11 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 10 ) , acute megakaryoblastic leukemia (M7) ( 10 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 10 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 10 ) , acute myeloblastic leukemia, without maturation (M1) ( 10 ) , T cell leukemia ( 12 ) , B cell lymphoma ( 10 ) , non-Hodgkin's lymphoma ( 10 ) , ovarian cancer ( 5 ) , multiple myeloma ( 10 )
Relevant cell line - cell type - tissue:
786-O (renal) [VHL (human), transfection] ( 3 ) , 786-O (renal) ( 3 ) , A498 (renal) ( 13 ) , AML-193 (monocyte) ( 10 ) , breast ( 1 , 5 ) , CMK (megakaryoblast) ( 10 ) , CTS (myeloid) ( 10 ) , DOHH2 ('B lymphocyte, precursor') ( 10 ) , HEL (erythroid) ( 10 ) , Jurkat (T lymphocyte) ( 7 , 14 ) , K562 (erythroid) ( 9 ) , Kasumi-1 (myeloid) ( 10 ) , KG-1 (myeloid) ( 10 , 11 ) , Kit225 (T lymphocyte) ( 12 ) , liver ( 6 ) , MV4-11 (macrophage) ( 10 ) , OPM-2 (plasma cell) ( 10 ) , ovary ( 5 ) , P31/FUJ (erythroid) ( 10 ) , RL ('B lymphocyte, precursor') ( 10 ) , RPMI-8266 (plasma cell) ( 10 ) , SU-DHL-6 (B lymphocyte) ( 10 ) , U266 (plasma cell) ( 10 )

Upstream Regulation
Putative in vivo kinases:
PKCT (human) ( 4 )
Kinases, in vitro:
PKCT (human) ( 4 )
Treatments:
IL-2 ( 12 ) , ischemia ( 5 )

Downstream Regulation
Effects of modification on ARHGEF6:
activity, induced ( 4 )
Effects of modification on biological processes:
cell growth, induced ( 4 ) , cell motility, induced ( 4 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

3

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

4

Llavero F, et al. (2015) Guanine nucleotide exchange factor αPIX leads to activation of the Rac 1 GTPase/glycogen phosphorylase pathway in interleukin (IL)-2-stimulated T cells. J Biol Chem 290, 9171-82
25694429   Curated Info

5

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

6

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

7

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

8

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

9

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

10

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

11

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

12

Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91
21722762   Curated Info

13

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

14

Tao WA, et al. (2005) Quantitative phosphoproteome analysis using a dendrimer conjugation chemistry and tandem mass spectrometry. Nat Methods 2, 591-8
16094384   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.